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Peptide nucleic acids (PNAs) bind duplex DNA in
a sequence-specific manner, creating triplex struc-
tures that can provoke DNA repair and produce
genome modification. CCR5 encodes a chemokine
receptor required for HIV-1 entry into human cells,
and individuals carrying mutations in this gene are
resistant to HIV-1 infection. Transfection of human
cells with PNAs targeted to the CCR5 gene, plus
donor DNAs designed to introduce stop codons
mimicking the naturally occurring CCR5-delta32
mutation, produced 2.46% targeted gene modifica-
tion. CCR5 modification was confirmed at the DNA,
RNA, and protein levels and was shown to confer
resistance to infection with HIV-1. Targeting of
CCR5 was achieved in human CD34+ hematopoietic
stem cells (HSCs) with subsequent engraftment into
mice and persistence of the gene modification
more than four months posttransplantation. This
work suggests a therapeutic strategy for CCR5
knockout in HSCs from HIV-1-infected individuals,
rendering cells resistant to HIV-1 and preserving
immune system function.
INTRODUCTION
R5-tropic HIV-1 infection requires cell surface expression of both
the primary receptor, CD4, and CCR5, a seven transmembrane
G protein-coupled coreceptor, for viral entry. Hence, the CCR5
coreceptor has become an attractive target for development of
small-molecule entry inhibitors as well as for gene therapy
(Holt et al., 2010; Perez et al., 2008; Tsibris and Kuritzkes,
2007). A naturally occurring 32 bp deletion (CCR5-delta32)
produces a truncated protein that fails to localize to the cell
surface (Liu et al., 1996), providing individuals homozygous for
this mutation with immunity to R5 tropic HIV-1 (Samson et al.,
1996). In a recent report, an HIV-1-positive patient with acuteChemistry & Biology 18, 1189–119myeloid leukemia received an allogeneic stem cell transplant
with cells that were homozygous for the CCR5-delta32 mutation
(Hu¨tter et al., 2009). Posttransplantation, the recipient had no
detectable virus and had increased CD4 counts, demonstrating
reconstitution of the immune system.
The formation of triplex DNA structures by oligonucleotides
can stimulate recombination in a site-specific manner in human
cells (Knauert et al., 2006). Peptide nucleic acids (PNAs)
represent a class of synthetic oligonucleotides capable of triple
helix formation with high affinity and specificity for duplex
DNA. PNAs consist of purine and pyrimidine bases attached to
a polyamide backbone, maintaining a spacing similar to DNA
but yielding an achiral, neutrally charged molecule. Highly stable
PNA/DNA/PNA triplexes can be formed with two PNA strands
and the homopurine DNA strand of the duplex. One PNA strand
binds by strand invasion to the duplex via Watson-Crick pairing
in an antiparallel orientation, whereas the other can bind in the
major groove of the DNA/PNA duplex via Hoogsteen base pairs
(in a parallel orientation), forming a highly stable PNA/DNA/PNA
triplex, with displacement of the remaining DNA strand (Egholm
et al., 1993). If connected by a linker of sufficient flexibility, the
two PNA strands can be contained in a single molecule, yielding
a clamp structure upon DNA binding (PNA clamp).
To mimic the CCR5-delta32 mutation, we sought to perma-
nently alter the sequence of CCR5 in human cells using site-
specific, triplex-induced homologous recombination to insert
a stop codon in the vicinity of the delta32 mutation site. It was
expected that such a strategically placed stop codon would
result in a truncated protein, rendering modified human cells
resistant to R5-tropic HIV-1 entry.
Using a newly optimized design and the inherent ability of
triplex-forming PNAs to bind DNA and catalyze genomic modifi-
cation, we report here the generation of site-specific targeted
modification of the CCR5 gene in human cells, rendering them
permanently resistant to HIV-1 infection. This work provides
the basis for a new therapeutic strategy for AIDS and represents
a novel form of genomic medicine, whereby the CCR5 gene in
hematopoietic stem cells is permanently altered, allowing for
the proliferation of a reservoir of CCR5-negative, HIV-1-resistant
cell lineages, which can preserve immune function in infected
individuals.8, September 23, 2011 ª2011 Elsevier Ltd All rights reserved 1189
Figure 1. PNA-Stimulated Modification of the CCR5 Gene in Human THP-1 Cells
(A) Depiction of theCCR5 gene indicating the PNA binding site at bp 674-688 (purine stretch in bold) and the position of the delta32 deletion creating a stop codon
at 678.
(B) Diagram and gel mobility shift assays demonstrating binding of PNA-679, tcPNA-679, and tcPNA-684 to the polypurine target site in CCR5. J indicates
pseudoisocytosine substituted for C to allow pH-independent triplex formation. All PNAs have three lysine residues conjugated to each end and 8-amino-
2,6-dioxaoctanoic acid linkers were used as the flexible linker ‘‘O.’’
(C) AS-PCR assay in which the 30 end of the AS forward primer contains either the specific 6 bp mutation or the WT sequence. PNA binding site and relative
position of the 60 nt donor DNAs; either donor 597 or donor 591 are indicated. Sequences of the 6 bp mutations to be introduced in CCR5 by the donor DNAs.
Donor sequences are the reverse complement of those partially shown. Mutations are in bold, with resulting stop codons underlined.
(D) AS-PCR demonstrates targeted modification of theCCR5 gene in human THP-1 cells. THP-1 cells were transfected with donor 597, donor 597 and PNA-679,
donor 579 and tcPNA-679, donor 597 and tcPNA-684, or buffer alone. 48 hr posttransfection, genomic DNA was isolated, and AS-PCR was performed on
genomic DNA and controls as indicated.
(E) Quantification of PNA-inducedCCR5 gene targeting by enumeration ofCCR5-modified single-cell clones. THP-1 cells were transfectedwith either tcPNA-679
or PNA-679, plus donor DNA(s). 48 hr later the treated cell populations were diluted into multiwell plates to allow for isolation and analysis of single-cell clones by
AS-PCR of genomic DNA. The CCR2 gene was analyzed for modification by direct sequencing of 1740 clones.
See also Figure S1.
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Design of Molecules to Target CCR5
We designed a series of triplex-forming PNAs to bind to the
CCR5 gene at a polypurine stretch encompassing positions
679-688 (Figure 1A). PNA-679 forms a PNA clamp with Wat-
son-Crick and Hoogsteen (Egholm et al., 1993) binding domains
of equal length (Figure 1B), similar to PNA clamp designs used in
our prior work (Chin et al., 2008). To extend the length of the
recognition site beyond the homopurine sequence, we tested
a series of ‘‘tail-clamp’’ PNAs (tcPNAs) (Bentin et al., 2003).
tcPNA-679 binds to form a PNA/DNA/PNA triple helix ‘‘clamp’’
within the polypurine stretch at positions 679-688 of the CCR5
gene and also includes an additional 5 bp ‘‘tail,’’ forming
a PNA/DNA duplex at positions 674-678 (Figure 1B). This mole-
cule therefore mediates a mode of PNA binding to DNA that1190 Chemistry & Biology 18, 1189–1198, September 23, 2011 ª201encompasses both triplex and duplex formation (Bentin et al.,
2003; Kaihatsu et al., 2003) and in doing so targets a unique
15 bp sequence in the CCR5 gene. In this complex, the PNA/
DNA/PNA triple helix and the PNA/DNA duplex both produce
displacement of the pyrimidine-rich strand, creating an altered
helical structure that has been shown to provoke the nucleotide
excision repair (NER) pathway and activate the site for recombi-
nation with a donor DNA molecule. PNA/DNA/PNA triplexes
have been shown to stimulate NER on a plasmid substrate
even more than direct UV damage to the plasmid DNA (Rogers
et al., 2002). We also tested another tail-clamp PNA with an
extended tail but a shorter Hoogsteen binding domain (tcPNA-
684; Figure 1B). Based on an in vitro gel shift assay, all three
PNAs were found to bind to their specific CCR5 target sites in
a plasmid substrate at physiological pH, although tcPNA-679
clearly shows the greatest binding (Figure 1B).1 Elsevier Ltd All rights reserved
Figure 2. PNA-Induced Modification of CCR5 Is
Reproducible, Can Be Detected at the mRNA
Level, and Persists in Culture for More than Three
Months
(A) THP-1 cells were transfected with donor 597, donor
597 and tcPNA-679, or buffer alone and analyzed 48 hr
posttransfection by AS-PCR.
(B) Targeted modification of the CCR5 gene in K562 cells,
treated and analyzed as above.
(C) Demonstration of targeted CCR5 modification at the
mRNA level. Total mRNA was isolated from THP-1 cells
48 hr after transfection with donor 597, donor 597 and
tcPNA-679, or buffer alone and subjected to AS-RT-PCR.
(D) Long-term persistence of the targeted 597 mutation in
PNAanddonorDNA-treatedTHP-1cells afterup to98days
in culture as indicated, based on AS-PCR of genomicDNA.
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PNA-Induced CCR5 Gene Knockout in Human Stem CellsIn the strategy for PNA-induced recombination (Figure 1C),
PNA binding is expected to stimulate recombination between
the chromosomal CCR5 gene and a cotransfected donor DNA.
For this, two single-stranded antisense-oriented 60 nt donor
DNAs, 591 and 597, were designed to be homologous to
a portion of theCCR5 gene except for a central 6 bp segment in-
tended to introduce, via recombination, an in-frame stop codon
(Figure 1C) and create a sufficient sequence change to be easily
detectable by an allele-specific PCR (AS-PCR) assay
(Figure 1C).
CCR5 Targeting and Quantification in Human Cells
THP-1 cells, a human acute monocytic leukemia cell line that
expresses CCR5 and can be infected with HIV-1, were used as
an initial model to assay for targeted modification of CCR5
(Konopka and Du¨zgu¨nesx, 2002). THP-1 cells were mock-trans-
fected, transfected with donor 597 alone, or with donor 597
and one of the three PNAs. After 48 hr, genomic DNA was
prepared and analyzed by AS-PCR (Figure 1C). Introduction of
the targeted mutation into the CCR5 gene was produced at
a low level by the donor DNA alone but was substantially induced
by cotransfection of either PNA-679 or tcPNA-679with the donor
molecule (Figure 1D), whereas tcPNA-684 was less effective. As
an additional control to validate the assay, genomic DNA from
untreated cells was spiked in vitro with donor DNA, and then
the AS-PCR assay was performed. No signal was observed
under these conditions (see Figure S1A available online), elimi-
nating the possibility that any false-positive results could arise
from persistence of the donor DNAs.
To better quantify the PNA-induced recombination and to
establish the generation of cells with long-term, heritable
genomic modification, THP-1 cells were treated with either
PNA-679 or tcPNA-679 (in both cases plus donor DNA) and
then were diluted out into multiwell dishes. Single-cell clones
were obtained and individually assayed for CCR5 gene modi-
fication (Figure 1E). PNA-679 gave a targeted modification
frequency of 0.54%, consistent with the frequencies of induced
recombination by PNAs of this design previously reported for the
beta-globin gene target (Chin et al., 2008). However, tcPNA-679,
which showed superior target site binding in vitro (Figure 1B),
yielded 46 positive clones out of 1870 cell clones, for an overall
frequency of 2.46%. This increased activity may be attributed to
both increased binding affinity and greater disruption of the
underlying duplex target, thereby better provoking DNA repairChemistry & Biology 18, 1189–119and recombination, but this remains to be tested. These results
demonstrate the targeting for one allele. To test for the possibility
of double knockout of both alleles simultaneously, we treated
cells with tcPNA-679 and two different donors (591 and 597)
combined. 1870 cells were analyzed individually but a doubly
targeted clone was not found, giving an upper limit for the double
allele targeting frequency of less than or equal to 0.05%.
As a determination of potential off-target effects, the gene with
the highest homology to CCR5, the CCR2 gene, was directly
sequenced in clones isolated by limiting dilution from tcPNA-
679 and donor DNA-treated THP-1 cells. Analysis of the CCR2
sequence in 1740 cells revealed the presence of only wild-type
(WT) sequences, indicating no off-target changes, giving an
upper limit to the off-target frequency of less than 0.057% (Fig-
ure 1E). This is not surprising because the binding of tcPNA-
679 to the partially homologous region in CCR2 is reduced by
at least 4-fold compared with CCR5 (Figure S1B). Prior work
has established that even a small number of mismatches can
drastically reduce target site binding affinity and thereby
substantially diminish the ability of triplex-forming molecules to
induce recombination (Knauert et al., 2005). In work by Perez
et al. (2008) using CCR5-targeted zinc finger nucleases, off-
target modification of the CCR2 gene was determined to occur
at a frequency of 5.39%, only 6-fold less than their reported
frequency of CCR5 modification (35.6%). In contrast, our off-
target frequency is at least 43-fold lower than our frequency to
target CCR5 (2.46%) and at least two orders of magnitude less
than the off-target frequency reported by Perez for zinc-finger
nucleases, showing the greater specificity of the PNA-mediated
gene-targeting strategy. In addition, the region of theCCR5 gene
containing the PNA binding site was also directly sequenced in
960 cell clones from tcPNA-679- and donor DNA-treated cells,
and no sequence changes were found at or around the PNA
binding site (data not shown).
PNA-Induced Modification of CCR5 and Its Persistence
in Culture
Reproducible CCR5 gene targeting was seen not only in THP-1
cells but also in another human cell line, K562 (Figures 2A and
2B). Treated cells were also analyzed at the mRNA level using
allele-specific reverse transcriptase polymerase chain reaction
(AS-RT-PCR), confirming that the targeted sequence change is
present in themRNA expressed from theCCR5 gene (Figure 2C).
In addition, samples were taken intermittently from serially8, September 23, 2011 ª2011 Elsevier Ltd All rights reserved 1191
Figure 3. Targeted Modification of the CCR5 Gene in THP-1 Cells Yields Decreased CCR5 Protein Cell Surface Expression and Provides
Resistance to R5-tropic HIV-1 Infection
(A) AS-PCR to identify individual THP-1 cell clones carrying the 597 mutation or both the 597 and 591 mutations. Allele-specific primers were used to amplify the
597, 591, or WT CCR5 sequences from genomic DNA as indicated. WT and the respective mutant plasmids were used as PCR controls.
(B) Flow cytometry assessment of CCR5 cell surface expression in parental THP-1 cells versus CCR5-modified clones. THP-1 cells were treatedwith either buffer
or PMA (50 ng/ml) for 48 hr. Cells were collected and stained with a PE-conjugated CCR5 antibody and assayed by FACS to determine CCR5 protein expression
levels. Parental THP-1 cells, Mut591/WT heterozygous cells, and doubly modified Mut591/Mut597 THP-1 cells are represented by dark gray, black, and light gray,
respectively.
(C) Quantification of decreased cell surface CCR5 expression in parental and CCR5-targeted THP-1 cells, as above.
(D) Cell culture supernatant p24 levels were measured by ELISA at the indicated times after viral challenge. Parental THP-1 cells and Mut591/WT heterozygous
cells are in white and black, respectively. Results are graphed as the mean and standard deviation (SD) of duplicate determinations from two wells.
See also Figure S2.
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PNA-Induced CCR5 Gene Knockout in Human Stem Cellspassaged cell populations that had been treated with PNA-679
and donor 597. AS-PCR of these cell populations confirmed
that cells containing the targeted 597 mutation persisted for at
least 98 days in culture (Figure 2D), establishing that a heritable
sequence change had been generated and that the modified
cells are viable, further eliminating concern regarding any po-
tential PCR artifacts that could arise from transient persistence
of the donor DNA. Similarly, five clones isolated in the work
above were maintained in culture by serial passage for
13 months, and all five were confirmed to retain the targeted
modification in CCR5.
Isolation and Characterization of Single Cell-Modified
Clones: Effect on CCR5 Protein Expression and HIV-1
Infectibility
To generate a cell population with both CCR5 alleles modified,
one clone carrying the 597 modification (confirmed not only by
allele-specific PCR but also by genomic DNA sequencing to
have the modified allele) (Figure S2A) was expanded and trans-
fected with tcPNA-679 and DNA donor 591. From this treated
population, doubly mutant clones with both alleles modified
were identified by AS-PCR (Figure 3A). The frequency that
such clones were induced from the heterozygous cells was1192 Chemistry & Biology 18, 1189–1198, September 23, 2011 ª2010.98% (18/1840 clones). Note that in Figure 3A, the WT allele
seems to be present even in the compound heterozygous clone
because the two targeted modifications are not exactly in the
same location in the gene. Hence, the 30 end of what we refer
to as the ‘‘WT forward primer’’ that is used to amplify the control
band—when using the 591 donor—ends at the last 6bp of the
591 modification and does not overlap with the 597 mutation.
Therefore, this primer can still amplify off of the 597 modified
allele without any effect on the strength of the PCR product.
This PCR product is only presented in the figure as a control to
show that our samples contain genomic DNA with the human
CCR5 sequence.
The parental THP-1 cells, a heterozygous mutant (Mut597/WT)
clone, and a double mutant (Mut597/Mut591) clone were then
tested for targeted CCR5 modification at the protein level. For
this, we took advantage of the ability of phorbol myristate
acetate (PMA) to promote differentiation of THP-1 cells into a
macrophage-like state (Figure S2B), thereby yielding high levels
of CCR5 cell surface expression (Jagodzinski et al., 1999; Ko-
nopka and Du¨zgu¨nesx, 2002). In the parental THP-1 cells, PMA
treatment increased CCR5 mRNA expression approximately
5-fold, as assessed by a Taqman RT-PCR assay (Figure S2C),
and increased CCR5 protein cell surface expression 17-fold1 Elsevier Ltd All rights reserved
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ure S2D). The Mut597/WT heterozygous clone was treated with
PMA and determined by flow cytometry to have a 50% reduc-
tion in cell surface expression of CCR5 compared with WT/WT
cells (Figure 3B). The double mutant clone, Mut597/Mut591, had
minimal cell surface staining for CCR5 (essentially at the back-
ground level of the isotype staining in the assay), even after
PMA treatment (Figure 3B). These results, quantified in Fig-
ure 3C, show at the protein level that PNA plus donor DNA
treatment of THP-1 cells produces functional disruption of the
CCR5 gene, leading to reduced cell surface expression. This is
consistent with the introduction of stop codons by donors 591
and 597 to yield truncated proteins that fail to properly localize
to the cell membrane, thereby mimicking the effect of the
naturally occurring CCR5-delta32 mutation.
Because the goal of CCR5 gene targeting is to create a cell
population that is resistant to HIV-1 entry, we tested the
CCR5-modified THP-1 cells for infectibility by R5-tropic HIV-1
infection. After a single treatment of THP-1 cells with tcPNA-
679 and DNA donor 591, as described before, we isolated
Mut591/WT heterozygous clones. One randomly selected clone
was expanded and was seeded into multiwell plates at 2 3 105
cells per well in multiple replicates. In parallel, parental THP-1
cells, WT at the CCR5 locus, were seeded in the same manner.
The cells were treated with PMA for 48 hr to induce CCR5 cell
surface expression and then were challenged by addition of
live HIV-1BaL at a multiplicity of infection (moi) of 1. At 4, 6, 9,
10, and 12 days after infection, supernatants were harvested
and frozen. Upon completion of the time course, the superna-
tants were thawed and analyzed by enzyme-linked immunosor-
bent assay (ELISA) for core protein p24 antigen levels as
a measure of viral infection of the cells (Allain et al., 1987). The
ELISA results indicate a substantial decrease in HIV-1 infection
of the cells modified at the CCR5 locus by treatment with
tcPNA-679 and DNA donor 591 (Figure 3D), demonstrating
functional knockout of the CCR5 coreceptor (correlating further
with the CCR5 DNA, RNA, and protein expression analyses)
and establishing the endpoint of reduced HIV-infectibility of
PNA-modified human cells.
Modification of Human HSCs and Their Engraftment
Capability
For clinical application, ex vivomodification of HSCs fromHIV-1-
infected patients could offer a method to create a renewable
source of virus-resistant immune cells. Importantly, human
CD34+ HSCs have been shown to remain uninfected even in
HIV-1-infected patients (Shen et al., 1999). Hence, modification
of such cells would provide a source of HIV-1-resistant cell line-
ages. We tested the ability of tcPNA-679 plus donor DNA 597 to
modify the CCR5 gene in primary human CD34+ cells. The cells
were transfected by nucleofection with tcPNA-679 and donor
597, with donor 597 alone, or with buffer alone; and 24 or 48 hr
posttransfection cells were harvested for analysis of genomic
DNA and mRNA. The 597 mutation was detected in the CD34+
cells treated with donor alone, but in the population transfected
with tcPNA-679 and donor 597, the level of modification at the
target site was substantially higher (Figure 4A). The stimulation
of gene modification by tcPNA-679 was determined to be
approximately 12-fold as quantified by real-time AS-PCR (Fig-Chemistry & Biology 18, 1189–119ure 4B). To further quantify the targeting frequencies, a standard
curve was established by mixing genomic DNA from CCR5
heterozygous and WT cells in defined ratios. Real-time AS-
PCR was performed on the DNAs from the experimental
samples, and the results were quantified based on the standard
curve. CD34+ cells transfected with donor DNA alone were
calculated to have a modification frequency of 0.03%, whereas
the PNA-treated CD34+ cells were estimated to have a modifica-
tion frequency of 2.8% (Figure S3), a more than 90-fold increase
owing to the effect of the PNA. Importantly, targeted modifica-
tion in the CD34+ cells was also confirmed at the mRNA level
by AS-RT-PCR (Figure 4C), indicating that the successfully
modified CD34+ HSCs express mutant CCR5 mRNA. These
results support the feasibility of PNA-induced genomicmodifica-
tion in human primary cells.
It is important to note that the relative level of PNA-induced
gene modification of CCR5 was comparable or even higher in
CD34+ cells than in THP-1 cells. These results show not only
that primary human HSCs are susceptible to targeted gene
modification mediated by triplex-forming PNAs, but also that
effective gene modification in primary HSCs is highly dependent
on the stimulatory effect of the PNAs. Although some studies
have reported genome modification in transformed human and
rodent cell lines using single-stranded oligonucleotide donor
DNAs alone (Pierce et al., 2003), our results suggest that primary
HSCs aremuch less susceptible to this strategy and indicate that
the use of triplex-forming PNAs to stimulate recombination is
needed. There is, however, evidence that human stem cells
can be successfully modified by the use of donor DNA fragments
in the range of 500–600 bp (Goncz et al., 2006), but this approach
might be even better when combined with triplex-forming PNAs.
We next tested for the ability of PNA-modified CD34+ HSCs to
mediate human hematopoietic stem cell engraftment in immune-
deficient mice. CD34+ HSCs were transfected, as mentioned
before, with tcPNA-679 plus both donor 591 and donor 597.
Successful modification of the CCR5 gene was first confirmed
by AS-PCR after 24 hr in an aliquot of the treated cell population.
The treated cells were then transplanted into newborn NOD-scid
IL2rgnull HLA A2.1 mice via intracardiac injection (Figure 4D). At
four months posttransplant, peripheral blood cells from the
engrafted mice were harvested and fluorescence-activated cell
sorter (FACS) was used to confirm engraftment of the human
HSCs in the mice by the identification of cells carrying human
cell surface markers, including CD3, CD4, CD8, CD20, and
CD45 (Figure 4E). AS-PCR on genomic DNA isolated from the
mouse spleen was then performed to test for the presence of
the targeted modification of the human CCR5 gene in donor
human cells in the engrafted mice. The results show the pres-
ence of the targeted 591 and 597 mutations in the human
CCR5 gene persisting more than four months posttransplant in
the spleen of the mice transplanted with PNA-targeted human
CD34+ cells (Figure 4F), but not in the spleens of control mice.
Representative results from one of two transplanted mice are
shown; the results from the othermousewere similar. In addition,
CD4+ cells were isolated from the spleen of one of the trans-
planted mice at five months posttransplant, and these also
showed the targeted modifications in CCR5 (Figure 4G). These
data indicate that modification of primary HSCs via PNA and
donor DNA transfection does not disrupt their engraftment8, September 23, 2011 ª2011 Elsevier Ltd All rights reserved 1193
Figure 4. Targeted Modification of the CCR5 Gene in Human CD34+ HSCs and Engraftment in Mice
(A) CD34+ HSCs were transfected with either donor 597 alone or with donor 597 and tcPNA-679, or they were mock-transfected as indicated. One day later,
genomic DNA was isolated to detect targeted modification of the CCR5 gene by AS-PCR.
(B) Quantification ofCCR5 genemodification by quantitative real-time AS-PCR. Mean results from two replicates are shown, with error bars (expanded 1000x for
visualization) indicating SD. All samples were normalized to gene-specific primers.
(C) Targeted modification of CCR5 in CD34+ cells at the mRNA level by AS-RT-PCR.
(D) NOD-scid IL2rgnull HLA A2.1 mice were injected with treated CD34+ HSCs and allowed to engraft for 12 weeks. CD4-positive cells were isolated from the
spleen for analysis.
(E) FACS plots showing the engraftment of modified CD34+ cells in NOD-scid IL2rgnull HLA A2.1 mice. Presence of cells expressing human CD45 and CD20
indicate engraftment. Representative results from one of two mice are shown.
(F) Identification of targeted modification of the CCR5 gene in cells isolated from the spleen of mice that were injected with human CD34+ cells transfected with
tcPNA-679 plus donor 597 and donor 591. Genomic DNA was harvested from spleen four months posttransplant. Quantitative AS-PCR was performed with both
591- and 597-specific primers. Samples include spleen from a control mouse, spleen from a mouse injected with unmodified CD34+ cells, and spleen from
a mouse injected with CD34+ cells transfected with tcPNA-679 plus donor DNAs. Similar results were seen in other transplanted mice.
(G) Quantitative AS-PCR was performed with both 591- and 597-specific primers (gray and black, respectively) on genomic DNA prepared from CD4+ T cells
isolated from a transplanted mouse and a control mouse.
See also Figure S3.
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PNA-Induced CCR5 Gene Knockout in Human Stem Cellscapability and still allows for multilineage repopulation, estab-
lishing that this approach to targeted gene modification could
provide the basis for a clinical therapy.
DISCUSSION
The results presented here show that PNAs capable of forming
site-specific PNA/DNA/PNA triple helices can stimulate recom-1194 Chemistry & Biology 18, 1189–1198, September 23, 2011 ª201bination in the endogenous CCR5 locus in human cells. Treat-
ment of cells with a CCR5-targeted tcPNA plus 60 nt donor
DNA molecules introduced stop codons into the CCR5 gene,
mimicking the naturally occurring CCR5-delta32 mutation.
Experiments in THP-1 cells confirmed targeted modification at
the DNA, RNA, and protein levels and showed persistence of
the targeted mutation in pooled cell populations for more than
three months in culture. By isolating individual clones from1 Elsevier Ltd All rights reserved
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PNA-Induced CCR5 Gene Knockout in Human Stem Cellstreated cell populations, we were able to directly quantify the
frequency of genomic modification, obtaining a targeting
frequency of approximately 2.46%. Direct sequencing of
a closely related gene, theCCR2 gene, showed nomodifications
in the 1740 cells analyzed, yielding an upper limit for the off-
target frequency in this highly homologous gene of less than
0.057%. Functionally, we found that targeted modification of
the CCR5 gene in THP-1 cells led not only to decreased cell
surface expression of the protein but also to a substantial
decrease in infectibility by R5-tropic HIV-1.
The application of tcPNAs as reported here represents their
first successful use for targeted gene modification in human
cells. Prior studies of tcPNAs highlighted their potential but
were focused on in vitro binding properties (Bentin et al.,
2003). Our results with the lysine-conjugated tcPNAs used
here demonstrate that this specialized PNA design can have a
robust effect leading to increased specificity, binding, and tar-
geting frequency. We had initially sought to use DNA-based
triple-forming oligonucleotide (TFOs) for this work, because
more than 10 years ago Belousov et al. reported the use of
a chlorambucil-conjugated DNA TFO for targeted binding to
the CCR5 gene (Belousov et al., 1998). However, this was
accomplished only in detergent permeabilized and consequently
dead cells. We followed up on this work, but we were not able to
develop any DNA or RNA-based TFOs to bind to the short
polypurine region in CCR5 in live cells even with the incorpora-
tion of several strategic base substitutions. The tcPNAs therefore
represent a major step forward in triplex technology for gene
targeting in human cells.
The targeting frequency of 2.46% in a single treatment may
already be sufficient for therapeutic application because
CCR5-deficient cells are known to have a selective advantage
in the face of HIV infection (Hu¨tter et al., 2009; Kumar et al.,
2008; Perez et al., 2008). However, we expect that further
increases in modification frequency may be possible. We
achieved a 5-fold increase by use of the tail-clamp PNAs and
we will continue to optimize PNA design to determine whether
further increases can be achieved. In addition, we are testing
treatment of the cells with chloroquine as a lysosome-disrupting
agent to enhance PNA bioavailabilty, SAHA (suberoylanilide
hydroxamic acid) as a histone deacetylase inhibitor to improve
chromosome accessibility, and encapsulation of PNAs and
DNAs in PLGA nanoparticles to increase transfection efficiency.
Early results suggest that these treatments may have positive
effects (Chin et al., 2008; Lonkar et al., 2009).
In addition, we have shown that PNA and donor DNA transfec-
tion can induce targeted gene modification in primary human
CD34+ HSCs and that this modification is increased 90-fold
with the addition of PNA to the donor DNA. Modified HSCs are
also capable of engrafting in NOD-scid IL2rgnull HLA A2.1 mice
and upon engraftment can produce multiple lineages of hemato-
poietic cells, including CD4+ cells, which have the targetedmodi-
fication. These experiments establish proof of principle for the
use of triplex-mediated gene targeting as a method to create
modified human hematopoietic progenitor cells as a potential
renewable source of HIV-1-resistant blood cell lineages.
Other strategies for modifying immune cells to resist HIV-1
include CCR5-directed ribozymes or siRNAs directed against
HIV-1-encoded RNAs. These are promising approaches butChemistry & Biology 18, 1189–119they require continual long-term expression for activity (Akkina
et al., 2003; Amado et al., 2004; Anderson and Akkina, 2005).
The use of zinc-finger nucleases to induce mutagenic double-
strand breaks in the CCR5 gene in CD4+ T cells has been re-
ported (Perez et al., 2008). However, expression of zinc-finger
nucleases requires complex viral vectors to introduce large
plasmid constructs, and the safety profile of such nucleases is
unknown. Importantly, in the work of Perez et al. (Perez et al.,
2008), using CCR5-targeted zinc finger nucleases, off-target
modification the CCR2 gene was determined to occur at
a frequency of 5.39%, only 6-fold less than their reported
frequency of CCR5 modification (35.6%). Our off-target fre-
quency is at least 43-fold less than our frequency to target
CCR5 (2.46%), showing the superior specificity of the PNA-
mediated gene targeting strategy. In a direct comparison, the
off-target frequency in CCR2 in our PNA-mediated approach,
with an upper limit of 0.057%, is at least two orders of magnitude
less than that produced by zinc-finger nucleases (Perez et al.,
2008). In fact, the use of triplex-forming DNA or PNA oligonucle-
otides has not yielded detectable mutagenesis in off-target
reporter genes such as cII or HPRT in analyses of more than
onemillion alleles (Rogers et al., 2004; Vasquez et al., 2000), sug-
gesting that the off-target effects are probably substantially
lower than the 0.057% upper limit calculated here. We expect
that this value will likely decrease as we sequence more alleles.
Hence, although PNA mediated targeting is about 10-fold
less efficient than by use of zinc-fingers, the off-target effects
are greatly reduced. Because zinc-finger nuclease-induced
double-strand breaks, leading to an unpredictable mixture of
mutations and chromosomal translocations, there is a risk of
induced leukemias and other deleterious events. PNA-mediated
approaches may be advantageous in this regard and may ulti-
mately carry much less risk of untoward side effects in patients.
Furthermore, the lack of off-target effects in CCR2 in spite of
partial homology to the tcPNA-679 binding site likely reflects
the mechanism of action of triplex-forming molecules for gene
modification. The capacity of triplexes to stimulate recombina-
tion comes from the ability of such altered helical structures to
provoke DNA repair via the nucleotide excision repair pathway
(Chin et al., 2008; Datta et al., 2001; Rogers et al., 2002; Wang
et al., 1996). To stimulate DNA repair, the PNA or DNA oligonu-
cleotides must bind extremely tightly to the DNA. Mismatches
can reduce the binding enough so that the ability to induce
recombination is greatly diminished (Knauert et al., 2005). With
reduced affinity, such loose binding oligomers—even if they
do bind—can be easily removed from the DNA by helicases.
Importantly, the PNAs have no intrinsic nuclease activity them-
selves (unlike zinc finger nucleases), and so they must bind
tightly to their target to have any effect by triggering DNA repair.
In light of this mechanism, it is therefore not surprising that there
are very low off-target effects at mismatched sites, even if they
are only partially mismatched.
The PNA-based approach described here uses chemically
synthesized oligonucleotides, a class of agents that has been
extensively studied in clinical trials with an overall favorable
safety profile (Vasquez et al., 2000; Vasquez et al., 1999). Plus,
the PNA-induced modification in CCR5 is templated by the
donor DNAs, leading to a precisely prescribed sequence
change. As such, the work reported here establishes proof of8, September 23, 2011 ª2011 Elsevier Ltd All rights reserved 1195
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CCR5 can be achieved in primary human CD34+ HSCs as
a means to provide a long-term source of cell lineages, consti-
tuting a potential therapy for HIV-1 infection. The work presented
here could also be used for other genetic diseases, allowing for
precise genomic modifications to correct or introduce mutations
in targeted genes for both research and gene therapy.SIGNIFICANCE
CCR5 encodes a chemokine receptor required for HIV-1
entry into human cells, and individuals carrying a naturally
occurring 32bp deletion mutation in this gene are resistant
to HIV-1 infection, thus making CCR5 an attractive target
for gene therapy. Bifunctional triplex-forming peptide nu-
cleic acids (PNAs) that consist of linked Hoogsteen and
Watson-Crick binding domains can form PNA/DNA/PNA
triplexes. These triplexes can induce DNA repair and
stimulate recombination of target genes with donor DNAs
in human cells. CCR5-targeted PNAs were optimized to
contain a ‘‘tail’’ on the Watson-Crick domain to provide
increased duplex invasion and greater binding specificity,
yielding a substantial increase in targeting efficiency in
human cells. Site-specific disruption of the CCR5 gene
was achieved in 2.46% of human cells in a single treatment,
a frequency estimated to be clinically relevant. The targeted
modification was designed to mimic the naturally occurring
CCR5-delta32mutation and thus render the cells resistant to
HIV-1 infection. This was confirmed by direct challenge of
PNA-modified human cells with live virus, thereby directly
establishing that this strategy inhibits HIV-1 infection of
human cells.
This work describes an advancement in triplex technology
for intracellular gene targeting and presents the basis for its
use as a therapeutic strategy for AIDS: triplex-mediated,
permanent knockout, by sequence-specific genomic modi-
fication, of the CCR5 gene in hematopoietic stem cells
(HSCs) to create a reservoir of CCR5-mutated HSCs. Such
cells can give rise to multiple HIV-1-resistant cell lineages
and thereby preserve immune system function in HIV-1-
infected individuals.
This work may also lead to greater adoption of this
approach as a platform technology for site-specific manipu-
lation of the genome for both research and therapeutic
applications.EXPERIMENTAL PROCEDURES
PNAs and Oligonucleotides
tcPNA-679 (N- Lys-Lys-Lys-JTJTTJTTJT-OOO-TCTTCTTCTCATTTC-Lys-
Lys-Lys-C) was synthesized by Bio-Synthesis Inc. (Lewisville, TX) and purified
by reverse phase-high performance liquid chromatography (RP-HPLC). Three
lysines were conjugated to both the N- and C-terminal ends of the PNA
for increased bioactivity and 8-amino-2,6-dioxaoctanoic acid linkers were
used as the flexible linker ‘‘O.’’ DNA oligonucleotides were synthesized by
the Midland Certified Reagent Company Inc. (Midland, TX) and purified by
RP-HPLC. The sequences of the DNA oligonucleotides are (mutation sites in
bold) donor 591: 50 AT TCC CGA GTA GCA GAT GAC CAT GAC AGC TTA
GGG CAG GAC CAG CCC CAA GAT GAC TAT C 30 and donor 597: 50 TT
TAG GAT TCC CGA GTA GCA GAT GAC CCC TCA GAG CAG CGG CAG1196 Chemistry & Biology 18, 1189–1198, September 23, 2011 ª201GAC CAG CCC CAA GAT G 30. All oligonucleotides were 50 and 30 end-pro-
tected with three phosphorothioate internucleoside linkages.
Electrophoretic Mobility Shift Assays
Binding of PNAs to the CCR5 target site was determined by gel mobility shift
assays using a plasmid containing the CCR5 or the CCR2 target site as
a substrate, as described (Kim et al., 2006).
Cell Culture
THP-1 and K562 cells were maintained in RPMI medium supplemented
with 10% FBS and L-Glutamine (GIBCO; Invitrogen, Carlsbad, CA). Human
CD34+ stem cells were isolated from apheresis of granulocyte colony stimu-
lating-factor (G-CSF)-mobilized peripheral blood from healthy donors and
then selected using a Baxter 300i Isolex Device and cryopreserved (Yale
Center of Excellence in Molecular Hematology). Cells were thawed and
maintained in StemSpan Serum-Free Expansion Media supplemented with
StemSpan CC110 cytokine mixture (100 ng/ml rh Flt-3 Ligand, 100 ng/ml rh
Stem Cell Factor, 20 ng/ml rh IL-3, 20 ng/ml rh IL-6, StemCell Technologies
Inc., Vancouver, BC, Canada). THP-1 differentiation was induced by treat-
ment with phorbol 12-myristate 13-acetate (PMA) (Sigma, St. Louis, MO) at
50 ng/ml.
Electroporation of Molecules
THP-1 and K562 cells were electroporated at 350V, 12ms, 1 pulse using a BTX
Electo Square Porator ECM 830 (Harvard Apparatus, Holliston, MA) in 100 ml
phosphate-buffered saline (PBS) at indicated concentrations. After electropo-
ration, cells were transferred to plates containing RPMImediumwith 10%FBS
and L-Glutamine. Human CD34+ stem cells were thawed in media 24 hr before
transfection. Nucleofection was performed using an Amaxa Human CD34 Cell
Nucleofector Kit according to the manufacturer’s protocol (Lonza Group,
Basel, Switzerland). Cells were then plated in media, and 24 or 48 hr postnu-
cleofection, cells were collected by centrifugation for genomic DNA or RNA
isolation.
Genomic DNA/RNA Isolation
Genomic DNA was isolated from tissue culture samples using the Wizard SV
Genomic DNA Purification System (Promega, Madison, WI); from THP-1 cells
in 96-well plates, the Wizard SV 96 Genomic DNA Purification System was
used. RNA was isolated using the Absolutely RNA Miniprep Kit (Stratagene;
Agilent Technologies, Santa Clara, CA). Synthesis of cDNA from total RNA
samples was performed using the SuperScript First-Strand Synthesis System
(Invitrogen).
Allele-Specific PCR
Primers were designed to amplify a 400 bp region in CCR5. The allele-specific
forward primer was designed to contain the specific 6 bp mutations at the 30
end, while the WT forward primer contained the WT CCR5 sequence at the
same position. Primers were synthesized by the W.M. Keck Facility at Yale
University. Primer sequences and PCR conditions are available upon request.
PCR products were separated on a 1% agarose gel and visualized using a gel
imager.WT forward primers paired with the universal reverse primer were used
as a loading control. 3.2 mM donor 597 was added to an aliquot of untreated
THP-1 genomic DNAwith or without 6mM tcPNA-679. AS-PCR was performed
using untreated genomic DNA with or without PNA and donor to test the ability
of the donor DNA to act as a primer or a template in the reaction.
Infectibility
THP-1 cells were induced to differentiate into adherent macrophage-like cells
by treatment with PMA. Cells were plated at 23 105 cells/well in 96 well plates
and treated with 50 ng/ml PMA for 48 hr at 37C and washed thoroughly.
Seven days after differentiation, PMA-treated THP-1 (THP-1/PMA) cells
were exposed to HIV-1BaL at an MOI of 1. After a 4 hr incubation at 37
C
with the virus, cells were washed three times and cultured in 10% RPMI
medium. Infection was monitored by the viral p24 level in harvested culture
supernatants (harvested on days 4, 6, 8, 10, and 12 postinfection) using ELISA
plates obtained from PerkinElmer Life Sciences (Waltham, MA). Results are
expressed as the mean and standard deviation (SD) of duplicate determina-
tions from two wells. To calculate moi, HIVBaL was titrated on 1 3 10
5 primary1 Elsevier Ltd All rights reserved
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cellular p24 antigen was measured by flow cytometry. Based on this, 100 ng
p24 gag antigen equivalents per well was determined to be the TCID50
(moi = 0.5).
Mouse Transplantation
All animal use was in accordance with the guidelines of the Institutional Animal
Care and Use Committee (IACUC) of the University of Massachusetts Medical
School and The Jackson Laboratory, and conformed to the recommendations
in theGuide for the Care and Use of Laboratory Animals (Institute of Laboratory
Animal Resources et al., 1996). Targeted or untreated humanCD34+ cells were
resuspended in RPMI medium supplemented with 1% fetal calf serum.
NOD.Cg-Prkdcscid Il2rgtm1Wjl/Sz Tg(HLA-A2/H2-D/B2m)1Dvs/Sz (NOD-scid
IL2rgnull HLA-A2.1) mice have been described previously and were obtained
from the research colony maintained by L.D.S. at The Jackson Laboratory
(Jaiswal et al., 2009). 4 3 105 CD34+ cells in 50 ml were injected into two
newborn NOD-scid IL2rgnull HLA A2.1 mice by intracardiac injection. Twelve
weeks postinjection mice were bled and analyzed by FACS to determine
engraftment of human hematopoietic cells. Mice were sacrificed, and various
tissues were harvested and flash frozen. CD4-positive cells were isolated from
one fresh spleen sample from a PNA plus donors-treated mouse using BD
IMag anti-human CD4 particles (BD Biosciences, Franklin Lakes, NJ).
Genomic DNA was isolated from tissues by phenol/chloroform extraction
and analyzed by quantitative real-time AS-PCR.
Quantitative Real-Time AS-PCR
Quantitative PCR was performed using Brilliant SYBR Green qPCR reagents
on the Mx3000p real-time PCR system (Stratagene). Fluorescence intensity
was monitored in real time, and cycle threshold cycles (CTs) were calculated
based on dRn fluorescence with an adaptive baseline using the software
supplied with the MX3000p. Comparative quantification was performed by
comparing the CTs obtained from amplification of CCR5 to those observed
using gene-specific primers (forward: 50 ACCTTTGGGGTGGTGACAAGTGTG
30; reverse: 50 TCTCCCCGACAAAGGCATAGATGA 30) as a normalizer.
Relative mutant CCR5 abundance was calculated using the -DDCT method
(Stratagene). All assays were preformed in duplicate.
Set ratios of genomic DNA fromWT and 597 heterozygous cells were mixed
to create a standard curve to quantify targeting frequencies in treated cells.
Standard curve samples were run in duplicate along with genomic DNAs
from treated cells of unknown targeting frequency. Using the -DDCT method
(Livak and Schmittgen, 2001), values were obtained and plotted to create
a standard curve. The equation for this curve was then used to calculate the
targeting frequency of the unknown samples.
AS-RT-PCR
Primers were designed to amplify a 667 bp region in CCR5. The AS reverse
primer was designed to contain the specific 6 bp mutation at the 30 end,
whereas the WT reverse primer contained the WT CCR5 sequence. Forward
primers were designed to bind in exon 2 with the reverse primer binding within
exon 3, allowing for specific identification of cDNA as opposed to genomic
DNA-amplified products. Primer sequences and PCR conditions available
are upon request. The PCR products were separated on a 1% agarose gel
and visualized using a gel imager. The forward primer paired with the WT
reverse primer was used as a loading control.
Taqman Assay for RNA Induction
To test CCR5mRNA expression, cDNA was prepared from total RNA samples
from PMA induced and uninduced THP-1 cells. cDNA was used in PCR reac-
tions containing TaqmanUniversal master mix, premixed Taqman probes, and
reference dye (Applied Biosystems, Life Technologies, Carlsbad, CA) in a final
volume of 25 ml. Data were analyzed as previously described (Bindra et al.,
2005; Bindra and Glazer, 2007). The amplification scheme was: 50C for
2 min, 95C for 10 min, 95C for 15 s, and 60C for 1 min for 45 cycles
preformed using the Mx3000p RT-PCR system (Stratagene). Fluorescence
intensity was monitored in real time, and CTs were calculated based on dRn
fluorescence with an adaptive baseline using the software supplied with the
MX3000p. Comparative quantification was performed by comparing the CTs
obtained from amplification of CCR5 with those observed for 18S rRNA asChemistry & Biology 18, 1189–119a normalizer. Relative mRNA abundance was calculated using the -DDCT
method (Stratagene). CCR5 probes were FAM labeled, and the 18S probe
was MGB-labeled (obtained from Applied Biosystems). All assays were
performed in duplicate.
Cell Surface Staining
To test for the presence of CCR5 at the cell surface, 2 3 106 cells were incu-
bated with PMA dissolved in dimethyl sulfoxide (DMSO) to a final concentra-
tion of 50 ng/ml in culture medium, or mock treated with DMSO alone for
48 hr. Cells were then collected, washed in PBS, and then washed in CCR5
staining buffer (2% FBS-certified [GIBCO], 1% sodium azide [10% w/v solu-
tion], and PBS [GIBCO]). Cell pellets were then resuspended in CCR5 staining
buffer and functional grade purified anti-mouse CD16/32 (eBioscience, Inc.,
San Diego, CA) was added to THP-1 cells for blocking. Cells were allowed
to incubate at room temperature for 10 min before being split into fresh tubes
containing either a PE-conjugated anti-hCCR5 or Mouse IgG1 Isotype Control
antibody (R&D Systems, Inc., Minneapolis, MN) and kept on ice for 20 min.
Cells were then pelleted, and the supernatant was removed. 500 ml of CCR5
staining buffer was used to wash the cells before they were resuspended
in PBS for FACS. Samples were analyzed on a FACSCalibur with CellQuest
software (Becton Dickinson, Franklin Lakes, NJ).
Sequence Analysis
Gene-specific primers (forward: 50 ACCTTTGGGGTGGTGACAAGTGTG 30
and reverse: 50 TCTCCCCGACAAAGGCATAGATGA30) were used to amplify
a 400 bp region of the CCR5 locus. PCR products were gel-purified using
the QIAquick gel purification kit (QIAGEN, Venlo, The Netherlands). Purified
PCR products were sequenced by the W.M. Keck Facility at Yale University.
A 420 bp region of the CCR2 gene encompassing the most homologous
region to CCR5 (FASTA 4201-4621) was amplified by PCR (forward: 50
CCTGGCTATTGTCCATGCTG 30; reverse: 50 CTTTCACAGTTACTCAGGCCG
30). The resulting PCR products were sequenced by the W.M. Keck Facility
at Yale University.
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